Date: 25 June, 2018 It is my proud privilege to deliver the annual convocation address of India’s iconic institution for advanced scientific education and research. At the outset, let me offer my felicitations to the medal winners, the graduating students and their families on this proud day. My congratulations also to the faculty, the Governing … Continue reading Academia Must Inspire Society through Science
New Government Should Focus on Inclusive Development of Karnataka
By - Kiran Mazumdar- Shaw, President, B.PAC and CMD, Biocon The results of the Karnataka Assembly elections have fallen short of giving an absolute majority to any party paving the way for alliances which has set in a bit of uncertainty. Irrespective of which alliance forms the government, Karnataka needs a stable government that carries … Continue reading New Government Should Focus on Inclusive Development of Karnataka
Karnataka Needs Political Maturity Not One-upmanship
By - Kiran Mazumdar- Shaw, President, B.PAC Karnataka’s business-friendly policies for knowledge-based industries such as information technology and biotechnology have won it the epithets of ‘IT Capital’, ‘BT Capital’ and ‘Startup Capital’. The leadership assumed by the state is not an accident. It is the result of a decade long strong collaboration between government, industry and … Continue reading Karnataka Needs Political Maturity Not One-upmanship
From Brewing to Biologics: Kiran Mazumdar-Shaw in conversation with Catherine Jewell, Communications Division, WIPO
Kiran Mazumdar-Shaw shares with Catherine Jewell, her story of innovation and entrepreneurship; Her journey from brewing to creating Biocon, Asia's leading Biopharmaceutical Company.
It’s Time for India’s Youth to Stand Up and be Counted
By Kiran Mazumdar-Shaw, CMD, Biocon The Lok Sabha elections in 2019 will be historic! An entire generation that was born at the turn of the 21st century will have turned 18 and thus become eligible to vote! 133 million young adults will get to exercise their franchise and thus give shape to their idea of … Continue reading It’s Time for India’s Youth to Stand Up and be Counted
REALISING THE GAME CHANGING POTENTIAL OF NHPS
The NDA government’s announcement of a health insurance scheme covering 500 million poor and needy Indians is indeed laudable. An estimated 75 million Indians are driven to bankruptcy and poverty each year because they have to pay over 60% of hospitalisation costs out of their own pockets. Given the dismal healthcare scenario, the NHPS can … Continue reading REALISING THE GAME CHANGING POTENTIAL OF NHPS
IHC Public Lecture: Strategic Importance Of Data Sciences In Research And Innovation
DATA IS KING In 2012, IDC projected that the digital universe will reach 40 zettabytes by 2020. This was based on the assumption that 1.7 megabytes of new information will be created every second for every human being on the planet in 2020. IDC realised that its projection was on the conservative side! Its current … Continue reading IHC Public Lecture: Strategic Importance Of Data Sciences In Research And Innovation
An Inclusive Budget
By Kiran Mazumdar Shaw The Finance Minister has presented a comprehensive and wide-ranging Budget for FY19, which addresses most of the areas that need focus to ensure sustainable, long-term and equitable growth of the Indian economy. The Union Budget needed to be prudent and forward-looking rather than populist and that is exactly what Finance Minister … Continue reading An Inclusive Budget
2017 – A Landmark Year for Indian Science
By Kiran Mazumdar Shaw, CMD, Biocon 2017 has been an exciting year for science in India. From unheralded incremental innovations to Big Bang headline-grabbing global feats, Indian scientists have done some very important work to push the frontiers of science during the year. India researchers made significant contributions to R&D across a broad spectrum of … Continue reading 2017 – A Landmark Year for Indian Science
A Journey of Endurance
By Kiran Mazumdar Shaw, CMD, Biocon The approval of our biosimilar Trastuzumab by the U.S. FDA is a vindication of our two-decade-long biologics-led pharmaceutical journey. We had invested ‘ahead of the curve’ in the promising future of targeted biologics at the turn of the millennium. At that time, we had anticipated some of the risks, … Continue reading A Journey of Endurance
